BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019
September 30, 2019 06:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against BeiGene, Ltd. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
September 25, 2019 09:55 ET
|
Schall Law
LOS ANGELES, Sept. 25, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
September 18, 2019 10:50 ET
|
Schall Law
LOS ANGELES, Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
September 13, 2019 17:06 ET
|
Schall Law
LOS ANGELES, Sept. 13, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
September 11, 2019 16:30 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update
September 08, 2019 01:01 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
September 03, 2019 08:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 03, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma
August 21, 2019 16:30 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 21, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Reports Second Quarter 2019 Financial Results
August 08, 2019 16:05 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
July 07, 2019 20:00 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., July 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...